fulvestrant has been researched along with Disease Exacerbation in 61 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 23 (37.70) | 29.6817 |
| 2010's | 28 (45.90) | 24.3611 |
| 2020's | 10 (16.39) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, J; Feng, J; Hu, X; Li, W; Liu, Q; Liu, Y; Ouyang, Q; Pan, Y; Shi, Y; Sun, T; Teng, Y; Tong, Z; Wang, X; Wang, Y; Wu, F; Wu, X; Xie, W; Xu, B; Yan, M; Yan, P; Yan, X; Yin, Y; Zhang, P; Zhang, Q; Zhu, X; Zou, J | 1 |
| Acar, Ö; Akagündüz, B; Aksoy, S; Alkan, A; Almuradova, E; Altınbaş, M; Artaç, M; Aslan, F; Avşar, E; Aydıner, A; Bayoğlu, İV; Bayram, E; Baytemür, NK; Celayir, ÖM; Çelebi, A; Çetin, B; Çiçin, İ; Dede, İ; Demir, H; Demir, N; Demirci, A; Demirel, BÇ; Doğan, M; Ebinç, S; Er, Ö; Erdem, D; Erdoğan, AP; Eren, T; Ergün, Y; Ertürk, İ; Erul, E; Geredeli, Ç; Gökmen, E; Gökmen, İ; Göksu, SS; Gülbağcı, BB; Gümüş, M; Hacıbekiroğlu, İ; İmamoğlu, Gİ; Işık, D; Kahraman, S; Kalender, ME; Kalkan, Z; Kanıtez, M; Karaboyun, K; Karacin, C; Karadağ, İ; Karadurmuş, N; Karakaya, S; Kayıkçıoğlu, E; Keskinkılıç, M; Korkmaz, T; Kut, E; Kuzu, ÖF; Menekşe, S; Mocan, EE; Nayır, E; Oksuzoglu, B; Oktay, E; Öktem, İN; Okutur, K; Oyman, A; Özdemir, Ö; Öztosun, B; Paksoy, N; Paydaş, S; Şahin, E; Şakalar, T; Sakin, A; Salim, DK; Selçukbiricik, F; Selvi, O; Şendur, MAN; Seyyar, M; Sönmez, Ö; Tanrıverdi, Ö; Teker, F; Türker, S; Uğraklı, M; Uluç, BO; Ünal, OÜ; Yaren, A; Yavuzşen, T; Yıldırım, N; Yılmaz, F; Yılmaz, H | 1 |
| Ishiguro, H; Iwakuma, N; Iwamoto, T; Kikawa, Y; Kobayashi, K; Masuda, N; Niikura, N; Oba, M; Okuno, T; Ozaki, S; Saji, S; Tada, H; Takeshita, T; Toh, U; Tsuneizumi, M; Watanabe, K; Yamamoto, Y | 1 |
| Cao, C; He, X; Li, H; Li, L; Wu, W; Yu, X; Zeng, Y | 1 |
| André, F; Catron, K; Chan, A; Chapman, SC; Gainford, MC; Goel, S; Hilton, JF; Im, SA; Johnston, SR; Kim, SB; Price, GL; Ricci, F; Tolaney, SM; Troso-Sandoval, TA; Wardley, AM; Yang, Z; Zambelli, S | 1 |
| Arrighi, A; Ballestrero, A; Becherini, P; Brandhorst, S; Caffa, I; Cea, M; Cilli, M; Clevers, H; Cortellino, S; Cremonini, AL; De Braud, F; Driehuis, E; Ferrando, L; Gradaschi, R; Longo, VD; Mantero, C; Mastracci, L; Monacelli, F; Nencioni, A; Odetti, P; Passalacqua, M; Piacente, F; Piazza, S; Provenzani, A; Salvadori, G; Spagnolo, V; Sukkar, SG; Tagliafico, A; Valdemarin, F; Vellone, VG; Vernieri, C; Wei, M; Zoppoli, G; Zucal, C | 1 |
| Cao, J; Gong, C; Hu, X; Li, Y; Tao, Z; Wang, B; Wang, L; Xie, Y; Zhang, J; Zhao, Y | 1 |
| Jerusalem, G; Neven, P; Sonke, GS | 1 |
| Gaofeng, P; Hexiao, T; Jinping, Z; Lanuti, M; Lecai, X; Li, S; Li, Z; Ming, X; Minglin, Z; Weidong, H; Xiao, Z; Xuefeng, Z; Yanhong, W; Yi, C; Yuquan, B; Zetian, Y; Zheng, T | 1 |
| Alba, E; Alvarez, E; Antón, A; Bermejo, B; Calvo, L; Carrasco, E; Casas, M; Ciruelos, E; Corsaro, M; Csöszi, T; de la Haba-Rodriguez, J; Gal-Yam, E; Garcia-Palomo, A; Gil-Gil, M; González-Santiago, S; Kahan, Z; Lang, I; López, IÁ; Margeli, M; Martín, M; Morales, S; Muñoz, M; Murillo, L; Ramos, M; Rodrigálvarez, G; Rodríguez, CA; Ruiz-Borrego, M; Servitja, S; Zielinski, C | 1 |
| Alves, CL; Bak, M; Bosch, A; Ditzel, HJ; Ehmsen, S; Gammelgaard, OL; Honeth, G; Hundebøl, MF; Johansen, LE; Kaminska, K; Lim, E; Portman, N; Terp, MG; Tuttolomondo, M | 1 |
| Jiang, A; Li, G; Ren, C; Wang, G; Yang, T; Yu, Z; Zhang, Q | 1 |
| Bachelot, T; Blau, S; Bordonaro, R; Ciruelos, E; Csőszi, T; Decker, T; Dharan, B; Di Leo, A; Egle, D; El-Hashimy, M; Janni, W; Johnston, S; Kalev, D; Lee, KS; Lønning, PE; Mouret-Reynier, MA; O'Regan, R; Schirone, A; Sellami, D; Tjan-Heijnen, VCG; Weber, D | 1 |
| Ahn, JS; Heo, MH; Im, YH; Kim, HK; Kim, JY; Lee, H; Park, YH | 1 |
| Baselga, J; Blumenstein, L; Bootle, D; Burris, HA; Demanse, D; Gil-Martin, M; Huang, A; Janku, F; Juric, D; Mayer, IA; Middleton, MR; Quadt, C; Rodón, J; Rugo, HS; Schuler, M; Schumacher, K; Seggewiss-Bernhardt, R | 1 |
| He, Q; Hu, ZY; Li, J; Liu, J; Ouyang, Q; Wang, H; Wang, Y; Xia, X | 1 |
| Chen, Z; Gong, C; Hu, S; Hu, X; Li, Y; Wang, B; Wang, L; Xie, Y; Yuan, P; Zhang, J; Zhang, Y; Zhao, Y | 1 |
| Clarke, RB; Dragoni, I; Gee, JM; Howell, SJ; Kedward, T; NicAmhlaoibh, R; Sabin, V; Santiago-Gómez, A; Simões, BM; Sims, AH; Trivier, E | 1 |
| Al-Mubarak, M; Amir, E; Ocana, A; Sacher, AG; Seruga, B; Vera-Badillo, F | 1 |
| Bliss, JM; Braybrooke, JP; Brunt, AM; Cameron, D; Cheung, KL; Coombes, G; Dodwell, D; Dowsett, M; Ellis, P; Folkerd, E; Hayward, L; Howell, A; Im, YH; Johnston, SR; Jyothirmayi, R; Kilburn, LS; Robinson, A; Sergenson, N; Sin, HJ; Wardley, AM; Wheatley, D | 1 |
| Helgason, CD; Mager, DL; Nakamura, H; Romanish, MT; Wang, Y; Xue, H | 1 |
| Bachelot, T; Duffy, S; Fleetwood, K; Glanville, J; Jerusalem, G; McCool, R; Varley, D; Zhang, J | 1 |
| Fan, Y; Gong, DD; Man, CF; Xu, J | 1 |
| Brown, M; de Vries, EF; de Vries, EG; Glaudemans, AW; Hospers, GA; Kema, IP; Schröder, CP; van Faassen, M; van Kruchten, M; van Lanschot, MC | 1 |
| Fan, S; Jiang, Z; Liao, Y; Liu, C; Tang, H; Wang, J; Xiong, J; Zhou, B; Zhou, S; Zou, M | 1 |
| Berset, C; Hasler-Strub, U; Hawle, H; Mamot, C; Mueller, A; Neven, P; Perey, L; Rochlitz, C; Rondeau, S; Rudolf, CB; Wiliders, H; Winterhalder, R; Zaman, K | 1 |
| Bogliolo, S; Cassani, C; Dominoni, M; Ferrero, S; Gardella, B; Iacobone, AD; Orlandini, A; Spinillo, A; Venturini, PL; Viazzo, F | 1 |
| Adachi, K; Enomoto, K; Fujisaki, S; Gonda, K; Hara, Y; Hirano, T; Masuo, Y; Nagashima, S; Sakurai, K; Suzuki, S; Tomita, R | 1 |
| Adhikari, VP; Dai, W; Kong, LQ; Li, X; Luo, QQ; Wu, H; Wu, KN; Wu, YT; Zhao, CX | 1 |
| André, F; Barrios, CH; Blackwell, K; Bonnefoi, H; Campone, M; Cortes, J; Denduluri, N; Deudon, S; Kahan, Z; Musolino, A; Neven, P; Shi, MM; Soliman, H; Squires, M; Zhang, Y | 1 |
| Ben-Yosef, R; Greenberg, J; Inbar, M; Ron, IG; Safra, T; Sarid, D; Yaal-Hahoshen, N | 1 |
| Ashraf, U; Chadha, MK; Escott, P; Lawrence, D; Levine, E; Payne, V; Silliman, C; Tian, L; Trump, DL | 1 |
| Barni, S; Gieseking, F; Kaufman, B; Neven, P; Nolè, F; O'Malley, FP; Petruzelka, L; Pritchard, KI; Robertson, JFR; Simon, SD; Steger, GG | 1 |
| Droz, JP; Féchon, A | 1 |
| Blesa, JM; Candel, VA | 1 |
| Benevides, CF; Chinen, LT; da Silva, SC; do Nascimento Matias, C; Fanelli, MF; Gimenes, DL; Mello, CA | 1 |
| Iwase, H; Iwata, H; Kamigaki, S; Masuda, N; Nakamura, S; Noguchi, S; Ohno, S; Rai, Y; Taniguchi, H; Yamamoto, N; Yoshida, M | 1 |
| Cardoso, F; Chang, J; Fukase, K; Ianuli, C; Kahan, Z; Lindemann, JP; Macpherson, MP; Mauriac, L; Neven, P; Panasci, L; Papai, Z; Pritchard, KI; Rolski, J | 1 |
| Chen, Z; Feng, J; Gu, K; Jiang, Z; Shao, Z; Song, S; Wang, C; Wang, J; Xu, B; Yang, J; Yu, S; Zhang, F; Zhang, Y | 1 |
| Edwards, RA; Farrell, NM; Jones, LT; Kraft, JM; Lech, GM; Lee, AR; Newman, MJ; Phantumvanit, V | 1 |
| Vergote, I | 1 |
| Howell, A | 2 |
| Bogart, DF; Castañeda, JM; Li, P; Lupu, R; Tsai, MS | 1 |
| Burton, G; Kleeberg, U; Mauriac, L; Osborne, CK; Robertson, JF; Vergote, I | 1 |
| Buzdar, A; Come, SE; Ellis, M; Gertler, S; Howell, A; Jones, SE; Kleeberg, UR; Mauriac, L; Morris, C; Osborne, CK; Robertson, JF; Vergote, I; Webster, A | 1 |
| Abram, P; Bajetta, E; Dimery, I; Elledge, R; Howell, A; Lichinitser, MR; Morris, C; Osborne, CK; Robertson, JF; Watanabe, T; Webster, A | 1 |
| Hardin, C; Jackson, T; Lefleur, B; Pommier, R; Toth-Fejel, S | 1 |
| Gradishar, W | 1 |
| Bartsch, R; Gnant, MF; Hussian, D; Jakesz, R; Locker, GJ; Pluschnig, U; Sevelda, U; Steger, GG; Wenzel, C; Zielinski, CC | 1 |
| Bernath, AM; Camoriano, JK; Fishkin, PA; Ingle, JN; Mirchandani, D; Nikcevich, DA; Perez, EA; Rowland, KM; Suman, VJ | 1 |
| Darbre, PD; Pugazhendhi, D; Sadler, AJ; Shaw, LE | 1 |
| Altorjai, G; Bartsch, R; Hussian, D; Locker, GJ; Mader, R; Pluschnig, U; Sevelda, U; Steger, GG; Wenzel, C; Zielinski, CC | 1 |
| Clément, P; Dietrich, D; Fiche, M; Goldhirsch, A; Hawle, H; Köberle, D; Nolé, F; Paridaens, R; Perey, L; Thürlimann, B; Wildiers, H; Zaman, K | 1 |
| Adamoli, L; Ascione, G; Catania, C; De Pas, T; Franceschelli, L; Goldhirsch, A; Magni, E; Medici, M; Nolè, F; Sanna, G; Torrisi, R; Verri, E | 1 |
| Greil, R; Hauser-Kronberger, C; Mayer, P; Mlineritsch, B; Moik, M; Namberger, K; Psenak, O | 1 |
| Esparaz, BT; Garnett, SA; Lower, EE; Wade, JL | 1 |
| Altorjai, G; Bartsch, R; Gnant, M; Jakesz, R; Mader, RM; Pluschnig, U; Rudas, M; Steger, GG; Wenzel, C; Zielinski, CC | 1 |
| Carcel-Trullols, J; Evans, TT; Higuchi, M; Mizumachi, T; Naito, A; Xie, CH | 1 |
| Abdou, NI; Greenwell, C; Kimler, BF; Li, X; Rider, V | 1 |
| Gornbein, J; Koeffler, HP; Miller, CW; Nakachi, K; O'Kelly, J; Said, JW; Sakashita, A; Xie, D | 1 |
7 review(s) available for fulvestrant and Disease Exacerbation
| Article | Year |
|---|---|
Ribociclib plus fulvestrant in the treatment of breast cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Female; Fulvestrant; Humans; Progression-Free Survival; Purines; Randomized Controlled Trials as Topic; Survival Rate | 2021 |
Fulvestrant for advanced breast cancer: a meta-analysis.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Neoplasm Staging; Treatment Outcome | 2013 |
Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Estradiol; Everolimus; Female; Fulvestrant; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Sirolimus; Treatment Outcome | 2014 |
Fulvestrant 250 mg versus anastrozole 1 mg in the treatment of advanced breast cancer: a meta-analysis of randomized controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Triazoles; Women | 2014 |
The role of fulvestrant in endometrial cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Biological Availability; Disease Progression; Endometrial Neoplasms; Estradiol; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Quality of Life | 2017 |
Fulvestrant in the treatment of postmenopausal women with advanced breast cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Postmenopause; Receptors, Estrogen; Signal Transduction | 2005 |
The future of fulvestrant ("Faslodex").
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen | 2005 |
23 trial(s) available for fulvestrant and Disease Exacerbation
| Article | Year |
|---|---|
Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Proliferation; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Disease Progression; Double-Blind Method; Female; Fulvestrant; Humans; Middle Aged; Piperidines; Placebos; Progression-Free Survival; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2021 |
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.
Topics: Aged; Aminopyridines; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Argentina; Australia; Benzimidazoles; Brazil; Breast Neoplasms; Disease Progression; Estrogen Receptor Antagonists; Europe; Female; Fulvestrant; Humans; Middle Aged; North America; Progression-Free Survival; Protein Kinase Inhibitors; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Republic of Korea; Signal Transduction; Time Factors; Trastuzumab | 2020 |
Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: Patient-reported outcomes in the PEARL study.
Topics: Androstadienes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Capecitabine; Disease Progression; Estrogen Receptor Antagonists; Europe; Female; Fulvestrant; Health Status; Humans; Israel; Neoplasm Metastasis; Patient Reported Outcome Measures; Piperazines; Postmenopause; Progression-Free Survival; Protein Kinase Inhibitors; Pyridines; Quality of Life; Time Factors | 2021 |
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease Progression; Disease-Free Survival; Double-Blind Method; Estradiol; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Middle Aged; Morpholines; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Time Factors; TOR Serine-Threonine Kinases; Treatment Outcome | 2018 |
Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Disease Progression; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Maximum Tolerated Dose; Middle Aged; Mutation; Progression-Free Survival; Protein Kinase Inhibitors; Receptors, Estrogen; Thiazoles; Time Factors | 2019 |
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentr
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Disease-Free Survival; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Neoplasm Metastasis; Nitriles; Postmenopause; Receptors, Estrogen; Triazoles | 2013 |
Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzimidazoles; Breast Neoplasms; Disease Progression; Double-Blind Method; Estradiol; Female; Fulvestrant; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Middle Aged; Placebos; Postmenopause; Protein Kinase Inhibitors | 2015 |
Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Disease Progression; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Postmenopause; Quinolones; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retreatment; Survival Analysis; Treatment Outcome | 2017 |
Phase II study of fulvestrant (Faslodex) in castration resistant prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Castration; Disease Progression; Dose-Response Relationship, Drug; Estradiol; Fulvestrant; Humans; Injections, Intramuscular; Kaplan-Meier Estimate; Male; Middle Aged; Prostatic Neoplasms; Receptors, Estrogen; Treatment Outcome | 2008 |
Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Asian People; Breast Neoplasms; Carcinoma, Ductal, Breast; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Postmenopause; Treatment Outcome | 2010 |
Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2).
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Canada; Disease Progression; Double-Blind Method; Estradiol; Estrogen Antagonists; Europe; Female; Fulvestrant; Humans; Kaplan-Meier Estimate; Middle Aged; Postmenopause; Receptors, Estrogen; Time Factors; Treatment Outcome | 2010 |
Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; China; Disease Progression; Double-Blind Method; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Nitriles; Time Factors; Treatment Outcome; Triazoles | 2011 |
Fulvestrant versus anastrozole as second-line treatment of advanced breast cancer in postmenopausal women.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Estradiol; Female; Follow-Up Studies; Fulvestrant; Humans; Nitriles; Postmenopause; Retrospective Studies; Treatment Outcome; Triazoles | 2002 |
Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Double-Blind Method; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Estradiol; Estrogen Receptor Modulators; Female; Follow-Up Studies; Fulvestrant; Humans; Letrozole; Megestrol Acetate; Middle Aged; Nitriles; Postmenopause; Retrospective Studies; Salvage Therapy; Treatment Outcome; Triazoles | 2003 |
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Double-Blind Method; Estradiol; Estrogen Antagonists; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Middle Aged; Nitriles; Postmenopause; Prospective Studies; Treatment Outcome; Triazoles | 2003 |
Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Disease-Free Survival; Double-Blind Method; Estradiol; Female; Fulvestrant; Humans; Injections, Intramuscular; Middle Aged; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 2004 |
Fulvestrant ('Faslodex') in pre-treated patients with advanced breast cancer: a single-centre experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Estradiol; Female; Fulvestrant; Genes, erbB-2; Humans; Middle Aged; Postmenopause; Receptors, Estrogen; Treatment Outcome | 2005 |
Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032.
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Drug Administration Schedule; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Middle Aged; Postmenopause; Treatment Outcome | 2006 |
Prognostic value of monitoring tumour markers CA 15-3 and CEA during fulvestrant treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Carcinoembryonic Antigen; Disease Progression; Estradiol; Female; Fulvestrant; Humans; Injections, Intramuscular; Middle Aged; Mucin-1; Predictive Value of Tests; Prognosis; Sensitivity and Specificity; Treatment Outcome | 2006 |
Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Postmenopause; Receptors, Estrogen; Salvage Therapy; Treatment Outcome | 2007 |
Fulvestrant ('Faslodex') in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Empathy; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Injections, Intramuscular; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Palliative Care; Program Evaluation; Prospective Studies; Quality of Life; Receptors, Estrogen; Receptors, Progesterone; Time Factors; Treatment Outcome | 2007 |
Evaluation of fulvestrant in clinical practice: use of an electronic data registry.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Estradiol; Female; Fulvestrant; Humans; Postmenopause; Treatment Outcome | 2007 |
Fulvestrant (Faslodex), an estrogen selective receptor downregulator, in therapy of women with systemic lupus erythematosus. clinical, serologic, bone density, and T cell activation marker studies: a double-blind placebo-controlled trial.
Topics: Adult; Antibodies, Antinuclear; Biomarkers; Bone Density; Calcineurin; CD40 Ligand; Disease Progression; Double-Blind Method; Down-Regulation; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Humans; Lupus Erythematosus, Systemic; Middle Aged; Quality of Life; Receptors, Estrogen; RNA, Messenger; Severity of Illness Index; T-Lymphocytes | 2008 |
31 other study(ies) available for fulvestrant and Disease Exacerbation
| Article | Year |
|---|---|
Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Everolimus; Female; Fulvestrant; Humans; Protein Kinase Inhibitors; Receptor, ErbB-2 | 2023 |
Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Female; Fulvestrant; Humans; Japan; Receptor, ErbB-2; Receptors, Estrogen; Triple Negative Breast Neoplasms | 2023 |
Applying vibration in early postmenopausal osteoporosis promotes osteogenic differentiation of bone marrow-derived mesenchymal stem cells and suppresses postmenopausal osteoporosis progression.
Topics: Animals; Bone Density; Bone Marrow Cells; Cell Differentiation; Collagen Type I; Core Binding Factor Alpha 1 Subunit; Disease Models, Animal; Disease Progression; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Antagonists; Female; Fulvestrant; Gene Expression Regulation; Humans; Mesenchymal Stem Cells; Osteocalcin; Osteogenesis; Osteoporosis, Postmenopausal; Ovariectomy; PPAR gamma; Rats; Rats, Sprague-Dawley; Signal Transduction; Tibia; Transcription Factors; Vibration | 2019 |
Fasting-mimicking diet and hormone therapy induce breast cancer regression.
Topics: Animals; Biological Factors; Breast Neoplasms; Diet Therapy; Diet, Healthy; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Early Growth Response Protein 1; Fasting; Female; Fulvestrant; Humans; Insulin; Insulin-Like Growth Factor I; Leptin; MCF-7 Cells; Mice, Inbred NOD; Mice, SCID; Piperazines; PTEN Phosphohydrolase; Pyridines; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Xenograft Model Antitumor Assays | 2020 |
Optimal duration of prior endocrine therapy predicts the efficacy of Fulvestrant in a real-world study for patients with hormone receptor-positive and HER2-negative advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Neoplasms; China; Disease Progression; Duration of Therapy; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Liver Neoplasms; Middle Aged; Progression-Free Survival; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Time Factors | 2020 |
Knockdown of CENPF inhibits the progression of lung adenocarcinoma mediated by ERβ2/5 pathway.
Topics: Adenocarcinoma of Lung; Animals; Chromosomal Proteins, Non-Histone; Computational Biology; Databases, Factual; Disease Progression; Estrogen Receptor Antagonists; Estrogen Receptor beta; Fulvestrant; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Lung Neoplasms; Mice; Mice, Nude; Microfilament Proteins; Signal Transduction | 2021 |
Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer.
Topics: Breast Neoplasms; Cell Line, Tumor; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Disease Progression; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Fulvestrant; Humans; Molecular Targeted Therapy; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt | 2021 |
RIZ1 is regulated by estrogen and suppresses tumor progression in endometrial cancer.
Topics: Animals; Cell Proliferation; Disease Progression; DNA-Binding Proteins; Down-Regulation; Drug Screening Assays, Antitumor; Endometrial Neoplasms; Estradiol; Estrogens; Female; Fulvestrant; Histone-Lysine N-Methyltransferase; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Experimental; Nuclear Proteins; Structure-Activity Relationship; Transcription Factors; Tumor Cells, Cultured | 2017 |
Clinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Disease Progression; Electronic Health Records; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Postmenopause; Progression-Free Survival; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Salvage Therapy; Time Factors | 2019 |
Clinical and genetic risk factors for Fulvestrant treatment in post-menopause ER-positive advanced breast cancer patients.
Topics: Adult; Breast Neoplasms; Circulating Tumor DNA; Disease Progression; Drug Resistance, Neoplasm; Female; Fulvestrant; Genetic Predisposition to Disease; Humans; Kaplan-Meier Estimate; Middle Aged; Mutation; Neoplasm Staging; Postmenopause; Probability; Prognosis; Proportional Hazards Models; Receptor, ErbB-2; Receptors, Estrogen; Risk Factors; Treatment Outcome | 2019 |
Treatment after Progression on Fulvestrant among Metastatic Breast Cancer Patients in Clinical Practice: a Multicenter, Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Breast Neoplasms; Capecitabine; Disease Progression; Everolimus; Female; Fulvestrant; Humans; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Receptor, ErbB-2; Retrospective Studies; Risk Factors; Survival Analysis; Treatment Outcome | 2019 |
PAK4 regulates stemness and progression in endocrine resistant ER-positive metastatic breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Down-Regulation; Drug Resistance, Neoplasm; Estrogen Receptor Antagonists; Female; Fulvestrant; Gene Expression; Humans; MCF-7 Cells; Meta-Analysis as Topic; Neoplasm Metastasis; Neoplastic Stem Cells; p21-Activated Kinases; Prognosis; Receptors, Estrogen; Small Molecule Libraries; Tamoxifen | 2019 |
Genistein versus ICI 182, 780: an ally or enemy in metastatic progression of prostate cancer.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Disease Progression; Estradiol; Estrogen Antagonists; Estrogen Receptor beta; Fulvestrant; Gene Expression Regulation, Neoplastic; Genistein; Humans; Male; Metallothionein; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Prostatic Neoplasms; RNA, Small Interfering; Treatment Outcome; Xenograft Model Antitumor Assays | 2013 |
Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Receptors, Estrogen; Tamoxifen; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
G protein-coupled estrogen receptor (GPER) mediates NSCLC progression induced by 17β-estradiol (E2) and selective agonist G1.
Topics: Adenocarcinoma; Aged; Animals; Apoptosis; Blotting, Western; Carcinogens; Carcinoma, Non-Small-Cell Lung; Cell Adhesion; Cell Movement; Cell Proliferation; Cyclopentanes; Disease Progression; Estradiol; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Immunoenzyme Techniques; Lung Neoplasms; Lymphatic Metastasis; Male; Mice; Middle Aged; Neoplasm Staging; Phosphorylation; Prognosis; Quinolines; Receptors, Estrogen; Receptors, G-Protein-Coupled; RNA, Small Interfering; Tissue Array Analysis; Tumor Cells, Cultured; Urethane; Xenograft Model Antitumor Assays | 2015 |
[Indoleamine 2,3-Dioxygenase Activity during Fulvestrant Therapy for Multiple Metastatic Breast Cancer Patients].
Topics: Adult; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Estradiol; Female; Fulvestrant; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Neoplasm Metastasis; Recurrence | 2016 |
Chemosensitization role of fulvestrant in combination with chemotherapy in postmenopausal hormone receptor positive and human epidermal growth factor negative metastatic breast cancer.
Topics: Administration, Oral; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Hormones; Humans; Neoplasm Metastasis; Postmenopause; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen | 2016 |
Fulvestrant in heavily pretreated metastatic breast cancer: is it still effective as a very advanced line of treatment?
Topics: Adult; Aged; Aged, 80 and over; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease Progression; Drug Administration Schedule; Estradiol; Estrogen Antagonists; Female; Follow-Up Studies; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Selective Estrogen Receptor Modulators; Tamoxifen | 2008 |
Activity of fulvestrant in HER2-overexpressing advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Disease Progression; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Models, Biological; Neoadjuvant Therapy; Receptor, ErbB-2; Retrospective Studies; Treatment Outcome; Up-Regulation | 2010 |
Do we really need new trials on fulvestrant in prostate cancer?
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Biomarkers, Tumor; Castration; Combined Modality Therapy; Disease Progression; Drug Administration Schedule; Estradiol; Fulvestrant; Humans; Injections, Intramuscular; Male; Prostate-Specific Antigen; Prostatic Neoplasms | 2010 |
PSA decrease with fulvestrant acetate in a hormone-resistant metastatic prostate cancer patient.
Topics: Acetates; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Compassionate Use Trials; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Drugs, Investigational; Estradiol; Fulvestrant; Humans; Injections, Intramuscular; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Retreatment | 2010 |
Prolonged time to progression with fulvestrant for metastatic breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cohort Studies; Disease Progression; Disease-Free Survival; Estradiol; Female; Fulvestrant; Genes, erbB-2; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies | 2011 |
Cost-effectiveness of fulvestrant 250 mg versus 500 mg in postmenopausal women with estrogen receptor-positive metastatic breast cancer and disease progression after antiestrogen therapy.
Topics: Breast Neoplasms; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Markov Chains; Models, Economic; Monte Carlo Method; Postmenopause; Receptors, Estrogen; United States | 2012 |
Selective oestrogen receptor downregulator.
Topics: Anastrozole; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Down-Regulation; Estradiol; Female; Fulvestrant; Humans; Nitriles; Receptors, Estrogen; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2002 |
Cyr61 promotes breast tumorigenesis and cancer progression.
Topics: Adenocarcinoma; Breast Neoplasms; Collagen; Cysteine-Rich Protein 61; Disease Progression; Down-Regulation; Drug Combinations; Drug Resistance, Neoplasm; Endothelial Growth Factors; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Immediate-Early Proteins; Intercellular Signaling Peptides and Proteins; Laminin; Lymphokines; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Proteoglycans; Receptors, Estrogen; Recombinant Fusion Proteins; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
Understanding the biologic mechanisms responsible for breast-cancer progression during tamoxifen or fulvestrant treatment.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Dehydroepiandrosterone Sulfate; Disease Progression; Estradiol; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Tamoxifen; Treatment Failure; Tumor Cells, Cultured | 2004 |
Changes in oestrogen receptor-alpha and -beta during progression to acquired resistance to tamoxifen and fulvestrant (Faslodex, ICI 182,780) in MCF7 human breast cancer cells.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Fulvestrant; Humans; Tamoxifen | 2006 |
Fulvestrant in heavily pre-treated patients with advanced breast cancer: results from a single compassionate use programme centre.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Empathy; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Injections, Intramuscular; Middle Aged; Program Evaluation; Prospective Studies; Receptors, Estrogen; Receptors, Progesterone; Time Factors; Treatment Outcome | 2007 |
Her2 and progesterone receptor status are not predictive of response to fulvestrant treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Disease Progression; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Postmenopause; Prospective Studies; Receptor, ErbB-2; Receptors, Progesterone; Treatment Outcome | 2007 |
Induction of acquired resistance to antiestrogen by reversible mitochondrial DNA depletion in breast cancer cell line.
Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Blotting, Southern; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Disease Progression; DNA, Mitochondrial; DNA, Neoplasm; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Ethidium; Female; Flow Cytometry; Fulvestrant; Humans; Neoplasms, Hormone-Dependent; Reverse Transcriptase Polymerase Chain Reaction; Tamoxifen | 2008 |
Breast cancer. Cyr61 is overexpressed, estrogen-inducible, and associated with more advanced disease.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Hormonal; Blotting, Northern; Breast Neoplasms; Carcinoma, Ductal, Breast; Cell Movement; Cells, Cultured; Cysteine-Rich Protein 61; Disease Progression; DNA, Complementary; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Gene Library; Growth Substances; Humans; Immediate-Early Proteins; Intercellular Signaling Peptides and Proteins; Mice; Mice, Nude; Middle Aged; Multivariate Analysis; Neoplasm Transplantation; Promoter Regions, Genetic; Protein Binding; Receptors, Estrogen; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Tamoxifen; Time Factors; Transfection; Tumor Cells, Cultured | 2001 |